These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32632135)

  • 1. β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline.
    Hammond TC; Xing X; Wang C; Ma D; Nho K; Crane PK; Elahi F; Ziegler DA; Liang G; Cheng Q; Yanckello LM; Jacobs N; Lin AL
    Commun Biol; 2020 Jul; 3(1):352. PubMed ID: 32632135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.
    Dang M; Chen Q; Zhao X; Chen K; Li X; Zhang J; Lu J; Ai L; Chen Y; Zhang Z
    Hum Brain Mapp; 2023 Feb; 44(2):327-340. PubMed ID: 36647262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S; Kuceyeski A; Raj A;
    J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
    Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCA7 Genotypes Confer Alzheimer's Disease Risk by Modulating Amyloid-β Pathology.
    Zhao QF; Wan Y; Wang HF; Sun FR; Hao XK; Tan MS; Tan CC; Zhang DQ; Tan L; Yu JT;
    J Alzheimers Dis; 2016 Mar; 52(2):693-703. PubMed ID: 27003212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease.
    Iaccarino L; Tammewar G; Ayakta N; Baker SL; Bejanin A; Boxer AL; Gorno-Tempini ML; Janabi M; Kramer JH; Lazaris A; Lockhart SN; Miller BL; Miller ZA; O'Neil JP; Ossenkoppele R; Rosen HJ; Schonhaut DR; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2018; 17():452-464. PubMed ID: 29159058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.
    Duong MT; Das SR; Lyu X; Xie L; Richardson H; Xie SX; Yushkevich PA; ; Wolk DA; Nasrallah IM
    Nat Commun; 2022 Mar; 13(1):1495. PubMed ID: 35314672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
    Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
    Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
    Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
    J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
    Takeda S
    Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.